Suchergebnisse - (Standardsuche:ritonavir)

PubPharm (192)

21

Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

enthalten in: HIV clinical trials | 2016

von Calza, L. | Danese, I. | Magistrelli, E. | +6

22

Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study

enthalten in: HIV clinical trials | 2016

von Teófilo, E. | Rocha-Pereira, N. | Kuhlmann, B. | +4

23

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy

enthalten in: HIV clinical trials | 2016

von Crespo, M. | Navarro, J. | Martinez-Rebollar, M. | +8

24

Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study

enthalten in: HIV clinical trials | 2016

von Nasta, P. | Salmon, D. | d'Arminio Monforte, A. | +5

25

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine

enthalten in: HIV clinical trials | 2015

von Young, B. | Squires, K. | Tashima, K. | +6

CommentOn: HIV Clin Trials. 2012 Sep-Oct;13(5):233-44. - PMID 23134624

26

Regimen selection in the OPTIONS trial of HIV salvage therapy : drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity

enthalten in: HIV clinical trials | 2015

von Tashima, K. | Mollan, K. | Na, L. | +8

27

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults

enthalten in: HIV clinical trials | 2015

von Grant, P. | Kitch, D. | McComsey, G. | +3

28

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain : The TRIP study

enthalten in: HIV clinical trials | 2015

von Pedrol, E. | Caro-Murillo, A. | Castaño, M. | +11

29

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age

enthalten in: HIV clinical trials | 2015

von Vera, J. | Jackson, A. | Dickinson, L. | +6

30

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age

enthalten in: HIV clinical trials | 2015

von Vera, J. | Jackson, A. | Dickinson, L. | +6